Programs

Phi Pharma initial focus in on innovative drug conjugates against acute myeloid leukaemia and leishmaniosis. Both programmes are in a lead-selection / optimisation phase. An adoptive transfer mouse model of a leukaemia cell line has provided proof of concept for the AML programme. The leishmaniosis programme has already attracted an initial collaboration with the Drugs for Neglected Diseases Initiative (DNDi).